Vitamin D deficiency is more common than you might think. Globally, studies suggest roughly one billion¹ people are vitamin D deficient. In the US alone, 42% ² of adults are deficient, while 50%³ of children aged between one and five and 70% of children aged between six and 11 have low vitamin D stores.
Since standards for minimum amounts are fairly low, I’d say a great number of people do not have enough vitamin D.
The treatment: The monkeys then received a single injection of the klotho protein. The dose was about five times their baseline levels and brought their total levels up to roughly what they’d be expected to have at birth.
They then completed the memory test again, and this time, they identified the right compartment about 60% of the time. The monkeys were tested multiple times over the next two weeks, and the improvement was sustained.
I have MS and my neurologist has me on high dose vitamin D (and have done pulse Mavenclad two years). Complete remission - although it’s probably more the Mavenclad which is a wonder drug for MS (although very very pricey. The cost for Mavenclad oral tablet 10 mg is around $39,863 for a supply of 4 tablets , depending on the pharmacy you visit. Although, free on the NHS in the U.K. Thank goodness for the NHS)
Several year ago at a Goldman Sack’s presentation. One of the people speaking, paraphrase
You do not want to invest in companies that are look for/or have cures for for diseases. You should invest in companies that have long term treatment’s. That target upper middle class, such as $30.000 per year in treatment cost for the person’s life time.
It’s disgraceful! It is a clear case of market failure. It’s like built in obsolescence with lightbulbs (but obviously much worse). I have a similar suspicion about longevity studies and their impact on retirement funds…